Incidence of AIDS-Defining Conditions Among Adults With Perinatally Acquired HIV After Transition to Adult HIV Care in the United States and Canada, 2000-2022.

Details

• Alternative Title:
  Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 2025, v. 81, no. 5: Incidence of AIDS-Defining Conditions Among Adults With Perinatally Acquired HIV After Transition to Adult HIV Care in the United States and Canada, 2000-2022.
• Journal Article:
  Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
• Personal Author:
  Haw, Nel Jason L. ; Lesko, Catherine R. ; Ng, Derek K. ; Lam, Jennifer O. ; Gebo, Kelly ; Sterling, Timothy R. ; Rabkin, Charles S. ; Li, Jun ; Buchacz, Kate ; Agwu, Allison ; Althoff, Keri
• Corporate Authors:
  North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
• Description:
  Little is known about the incidence of AIDS-defining conditions (ADCs) among people with perinatally acquired human immunodeficiency virus (PHIV) who transitioned to adult human immunodeficiency virus (HIV) care in the United States and Canada. We described the incidence among PHIV and compared it with that among those with non-perinatally acquired HIV (non-PHIV) and across calendar era.
  
  Using data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) from 2000-2022, we estimated weighted mean cumulative counts (MCCs) of ADCs, comparing people with PHIV and non-PHIV acquisition risk groups aged 18-40 years engaged in adult HIV care. The weights accounted for differences in characteristics among HIV acquisition risk groups as well as informative censoring. We calculated 95% confidence intervals using bootstrapping. We stratified results before and after 2012, when the immediate start of antiretroviral therapy was first recommended.
  
  There were 5429 ADCs among 22 950 people with HIV. Among those with PHIV, the MCC of ADCs by 3 years in adult HIV care was 26 per 100 persons (95% confidence interval, 15-40) in 2000-2011 and 16 per 100 (5-21) in 2012-2022. Within each calendar era, weighted MCCs of ADCs among people with PHIV were similar or lower than in non-PHIV groups. Within each HIV acquisition risk group, weighted MCCs of ADCs were lower in 2000-2011 than in 2012-2022.
  
  People with PHIV who transitioned to adult HIV care did not experience a greater ADC incidence than those with non-PHIV. This emphasizes the importance of continued engagement in adult HIV care, as it provides critical opportunities for ADC prevention and management.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Adult
  • Incidence
  • Male
  • Female
  • Young Adult
  • Adolescent
  • HIV Infections
  • Transition to Adult Care
  • Acquired Immunodeficiency Syndrome
  More +
• Keywords:
  • HIV
  • perinatally acquired
  • AIDS-defining conditions
  • lifetime survivors
• Source:
  Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 2025, v. 81, no. 5
• DOI:
  https://doi.org/10.1093/cid/ciaf300
• ISSN:
  1058-4838 ; 1537-6591
• Pubmed ID:
  40469005
• Pubmed Central ID:
  PMC12375960
• Document Type:
  Text
• Funding:
  K23 EY013707/EY/NEI NIH HHSUnited States/ ; R01 AI177010/AI/NIAID NIH HHSUnited States/ ; UL1 RR024131/RR/NCRR NIH HHSUnited States/ ; U01 HL146192/HL/NHLBI NIH HHSUnited States/ ; U01 AI069432/AI/NIAID NIH HHSUnited States/ ; K01 AI131895/AI/NIAID NIH HHSUnited States/ ; R01 AA016893/AA/NIAAA NIH HHSUnited States/ ; U01 DA036297/DA/NIDA NIH HHSUnited States/ ; U01 HL146241/HL/NHLBI NIH HHSUnited States/ ; Grady Health System/ ; P30 AI050409/AI/NIAID NIH HHSUnited States/ ; U01 HL146333/HL/NHLBI NIH HHSUnited States/ ; F31 AI124794/AI/NIAID NIH HHSUnited States/ ; P30 MH062246/MH/NIMH NIH HHSUnited States/ ; U01 AI069434/AI/NIAID NIH HHSUnited States/ ; National Institute for Mental Health/ ; R01 DA011602/DA/NIDA NIH HHSUnited States/ ; DC/NIDCD NIH HHSUnited States/ ; Government of Alberta/ ; Z01 CP010176/ImNIH/Intramural NIH HHSUnited States/ ; NR/NINR NIH HHSUnited States/ ; U54 GM133807/GM/NIGMS NIH HHSUnited States/ ; National Institute of Allergy and Infectious Diseases/ ; P30 AI094189/AI/NIAID NIH HHSUnited States/ ; U01 HL146245/HL/NHLBI NIH HHSUnited States/ ; P50 GM133807/GM/NIGMS NIH HHSUnited States/ ; Eunice Kennedy Shriver National Institute of Child Health & Human Development/ ; G12 MD007583/MD/NIMHD NIH HHSUnited States/ ; K24 DA000432/DA/NIDA NIH HHSUnited States/ ; U01 HL146205/HL/NHLBI NIH HHSUnited States/ ; U01 DA036935/DA/NIDA NIH HHSUnited States/ ; UM1 TR004406/TR/NCATS NIH HHSUnited States/ ; 90047713/HS/AHRQ HHSUnited States/ ; U01 AI038855/AI/NIAID NIH HHSUnited States/ ; U01 HL146208/HL/NHLBI NIH HHSUnited States/ ; TGF-96118/CAPMC/ CIHRCanada/ ; Ontario Ministry of Health and Long Term Care/ ; K01 AI157849/AI/NIAID NIH HHSUnited States/ ; R24 AI067039/AI/NIAID NIH HHSUnited States/ ; U01 HL146242/HL/NHLBI NIH HHSUnited States/ ; 90051652/HRSA/HRSA HHSUnited States/ ; U10 EY008057/EY/NEI NIH HHSUnited States/ ; U01 AI068636/AI/NIAID NIH HHSUnited States/ ; U01 AI038858/AI/NIAID NIH HHSUnited States/ ; CBR-86906/CAPMC/ CIHRCanada/ ; U01 HL146201/HL/NHLBI NIH HHSUnited States/ ; NS/NINDS NIH HHSUnited States/ ; U01 HL146193/HL/NHLBI NIH HHSUnited States/ ; U10 EY008052/EY/NEI NIH HHSUnited States/ ; U01 AA020790/AA/NIAAA NIH HHSUnited States/ ; HG/NHGRI NIH HHSUnited States/ ; UL1 TR002378/TR/NCATS NIH HHSUnited States/ ; R34 DA045592/DA/NIDA NIH HHSUnited States/ ; P30 AI027763/AI/NIAID NIH HHSUnited States/ ; U01 AI069918/AI/NIAID NIH HHSUnited States/ ; K24 AI118591/AI/NIAID NIH HHSUnited States/ ; K01 AI093197/AI/NIAID NIH HHSUnited States/ ; U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K01AI157849, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01AG053100, R01AI177010, R01DA011602, R01DA012568, R24AI067039, R34DA045592, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR002378, Z01CP010214, and Z01CP010176/NH/NIH HHSUnited States/ ; K24 AI065298/AI/NIAID NIH HHSUnited States/ ; U01 AA013566/AA/NIAAA NIH HHSUnited States/ ; N02 CP055504/CP/NCI NIH HHSUnited States/ ; CDC-200-2015-63931/CC/CDC HHSUnited States/ ; UL1 TR000083/TR/NCATS NIH HHSUnited States/ ; P30 AI027757/AI/NIAID NIH HHSUnited States/ ; U01 HL146204/HL/NHLBI NIH HHSUnited States/ ; National Institute of Dental & Craniofacial Research/ ; R01 DA012568/DA/NIDA NIH HHSUnited States/ ; U01 HL146202/HL/NHLBI NIH HHSUnited States/ ; CDC-200-2006-18797/CC/CDC HHSUnited States/ ; CBR-94036/CAPMC/ CIHRCanada/ ; KL2 TR000421/TR/NCATS NIH HHSUnited States/ ; CC999999/ImCDC/Intramural CDC HHSUnited States/ ; UL1 TR000004/TR/NCATS NIH HHSUnited States/ ; U01 HL146240/HL/NHLBI NIH HHSUnited States/ ; DK/NIDDK NIH HHSUnited States/ ; F31 DA037788/DA/NIDA NIH HHSUnited States/ ; R01 AG053100/AG/NIA NIH HHSUnited States/ ; U10 EY008067/EY/NEI NIH HHSUnited States/ ; P30 AI036219/AI/NIAID NIH HHSUnited States/ ; U01 HL146194/HL/NHLBI NIH HHSUnited States/ ; U24 AA020794/AA/NIAAA NIH HHSUnited States/ ; HCP-97105/CAPMC/ CIHRCanada/ ; U01 HL146203/HL/NHLBI NIH HHSUnited States/ ; U01 AI068634/AI/NIAID NIH HHSUnited States/ ; P30 AI050410/AI/NIAID NIH HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States ; Canada
• Pages in Document:
  962-969 (15 pdf pages)
• Volume:
  81
• Issue:
  5
• Download URL:
  https://stacks.cdc.gov/view/cdc/261363/cdc_261363_DS1.pdf
• File Type:
  [PDF - 285.96 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:9e3393d843bc255f7b165978c554199abb847add137565ece32237b8bd8898e236ad33f7ca1849d334696686bc8872edda4ed71f82d5db99d407d38dc083038c